

Serine and Cysteine Proteases and Their Inhibitors as Antimicrobial Agents and Immune Modulators

Bénédicte Manoury, Ali Roghanian, and Jean-Michel Sallenave

Abstract Proteases are not merely restricted to digestive purposes and remodeling of extracellular matrix and tissues, but are also key factors for the induction of physiological immune responses. This induction can be direct, through the degradation of pathogens within phagolysosomes, or indirect, through the activation of key pattern recognition receptors (PRRs), such as toll-like receptors (TLRs). Unfortunately, excess production of proteases leads to maladaptive host responses and excess tissue inflammation and damage. Although the mechanisms described here will apply to a variety of different organs, we will deal chiefly with processes occurring in the lung, in pathological conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). To combat these deleterious effects of proteases, the host fortunately produces antiproteases, which directly counteract the proteolytic activities of proteases. In addition to this “straight-forward” effect, novel “defensin-like” activities for these molecules are clearly now emerging, as it has recently been demonstrated that protease inhibitors can themselves help in restoring tissue homeostasis by inducing innate and adaptive responses, such as through their interaction with dendritic cells (DCs).

Bénédicte Manoury and Ali Roghanian authors contributed equally.

B. Manoury
Institut Curie U932, 24 rue d’Ulm, 75005 Paris, France

A. Roghanian
Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK

J.-M. Sallenave (✉)
Institut Pasteur, Unité de Défense Innée et Inflammation et Inserm U874, 25 rue du Dr. Roux,
75724 Paris Cedex 15, France

Inserm U874, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France

Université Paris, 7-Denis Diderot, Paris, France
e-mail: jms@pasteur.fr

Keywords Adjuvant • Antiproteases • Asparagine endopeptidase (AEP) • Dendritic cell (DC) • Elafin • Immune responses • Inflammation • Macrophage • Neutrophil elastase (NE) • Proteases • Secretory leukocyte protease inhibitor (SLPI) • Toll-like receptor (TLR)

1 Introduction

Proteases are classified on the basis of catalytic mechanism, and five known distinct classes are described: metallo, aspartic, cysteine, serine, and threonine. In humans, metallopeptidases are extremely diverse as they encompass 24 families, whereas cysteine proteases are represented by 19 families, serine proteases 17, and aspartic and threonine peptidases are represented by three families. For further generic information about this “degradome,” we refer the reader to recent reviews including [1] and [2].

Until recent times, the action of proteases was believed to be restricted to digestive purposes, extracellular modeling and/or remodeling of tissues, mainly through proteolytic activity on interstitial molecules, occurring throughout homeostasis and development or, in aberrant maladaptive circumstances, during disease pathogenesis. This view has clearly become untenable as proteases are clearly involved in a myriad of homeostatic as well as pathological processes. Similarly, several novel physiological functions have been attributed to endogenous antiproteases including antimicrobial and immunomodulatory activities.

We will discuss in this chapter the actions of proteases and antiproteases on physiological immune induction and inflammatory processes, as well as proteases-driven maladaptive responses. Although the mechanisms described here will apply to a variety of different organs, we will deal chiefly with processes occurring in the lung, as the protease/antiprotease balance in other tissues will be addressed by other contributors in this issue.

2 Toll-Like Receptors and Dendritic Cells in the Induction of Immune Responses

Mucosal surfaces are the first barriers against infections and their role is paramount in the prevention of systemic dissemination of pathogens. To perform this role in an unchallenged naive host, the latter uses both innate and adaptive immunity. The innate immune system is genetically programmed to detect invariant features of invading microbes. In contrast, the adaptive immune system, which is composed of T and B lymphocytes, employs antigen receptors that are not encoded in the germline but are generated *de novo* in each organism. Thus, adaptive immune responses are highly specific. The best-characterized microbial sensors are the so-called PRRs of the innate immune system, which detect relatively invariant

molecular patterns found in most micro-organisms [3]. These structures are referred to as pathogen-associated molecular patterns (PAMPs). Microbial pathogens are recognized through multiple, distinct PRRs that can be broadly categorized into secreted, transmembrane, and cytosolic classes. The transmembrane PRRs include the TLR family and the C-type lectins. TLRs in mammals are either expressed on the plasma membrane or in endosomal/lysosomal organelles [4]. Cell-surface TLRs recognize conserved microbial patterns that are accessible on the cell surface, such as lipopolysaccharide (LPS) of gram-negative bacteria (TLR4), lipoteichoic acids of gram-positive bacteria and bacterial lipoproteins (TLR1/TLR2 and TLR2/TLR6), and flagellin (TLR5), whereas endosomal TLRs mainly detect microbial nucleic acids, such as double-stranded RNA (dsRNA) (TLR3), single-stranded RNA (ssRNA) (TLR7), and dsDNA (TLR9) [5–8].

Innate immune cells bearing TLRs include DCs, macrophages, and neutrophils, among others. DCs are crucial immune cells detecting micro-organisms and linking innate to adaptive immunity. TLR signaling is linked to MyD88- and TRIF-dependent signaling pathways that regulate the activation of different transcription factors, such as nuclear factor (NF)- κ B. Specific interaction between TLRs and their ligands activates NF- κ B resulting in enhanced inflammatory cytokine responses, induction of DC maturation (e.g., upregulation of CD40, CD80, CD83, and CD86) and chemokine receptors (e.g., CCR7) [9]. These features have for a long time indicated that, in particular, TLR triggering switches the immature DC phenotype to an inflammatory phenotype that is capable of inducing adaptive immune responses, instructing both antigen-specific CD4⁺ and CD8⁺ T-cell responses and humoral responses.

2.1 Role of TLR9 in Inflammation and Immunity

Some studies suggest a role for TLR9 in the triggering of innate immune response to protozoan parasites as well as for some bacteria and viruses. For example, TLR9 is required for the development of the Th1-type inflammatory responses that follow oral infection with *Toxoplasma gondii* in mice from some inbred strains and is also implicated in the control of parasitemia during infection with *Trypanosoma cruzi*. The hemozoin pigment of *Plasmodium* or some parasite DNA associated with the pigment results in signaling through TLR9. More recently it has been shown that the early natural killer (NK) cell response to infection with *Leishmania donovani* was dependent on the secretion of IL-12 by myeloid DCs triggered in response to TLR9 stimulation [10]. TLR9-deficient (TLR9^{-/-}) mice have been recently described to be more susceptible to infection with *Leishmania major*. DCs lacking TLR9 failed to be activated by *L. major* probably suggesting that the DNA of *L. major* is a TLR9 ligand. Furthermore, *L. major*-infected TLR9^{-/-} DCs were unable to stimulate CD4⁺ T cells [11]. TLR9 ligands are known to be ssDNA carrying unmethylated CpG motifs [12]. A vast array of data indicates that TLR9 plays a key role in DNA-induced immunity and links it with a role in acquired

immunity through the activation of various cell types such as plasmacytoid DCs (pDCs), conventional DCs (cDCs), and B cells. Analysis of TLR9^{-/-} mice revealed that TLR9 is essential not only for proinflammatory cytokines production and other inflammatory responses but it also plays a role in the induction of Th1 acquired immune response and in the proliferation of B cells. In addition, TLR9 also recognizes bacterial and viral DNA. In particular, TLR9 cooperates with TLR2 to induce innate immune response against *Mycobacterium tuberculosis*. TLR9 also plays an important role in the fight against infections with *Brucella*, *Streptococcus pneumoniae*, and could be involved in recognition and clearance of *Helicobacter*. TLR9-mediated antiviral responses are largely documented. Indeed, mouse cytomegalovirus, herpes simplex virus type 1 and 2, and adenovirus are recognized by TLR9 on pDCs which produce high amount of interferon (IFN)- α in response to this stimulation. Recently, natural DNA repetitive extragenic sequences from *Pseudomonas aeruginosa* have been shown to strongly stimulate TLR9 [13]. In addition, signaling through TLR9 appears to be important in *P. aeruginosa* keratitis, and silencing TLR9 signaling reduces inflammation but contributes to decreased bacterial killing in the cornea [14].

3 Role of Proteases in the Induction of Immunity

3.1 Cysteine Proteases

Cysteine proteases were historically shown to have an important role in antigen presentation and the induction of immunity [15]. They are constitutively expressed in most cell types, especially in macrophages and DCs. They contain a cysteine thiol as part of their catalytic site and are related to papain and belong to the C1 family. Among them, cathepsins B, C, F, L, H, K, L, S, V and W have been isolated. Some of these enzymes are endopeptidases, whereas others are either amino or carboxy exopeptidases (see Table 1). Another endopeptidase named asparagine

Table 1 Lysosomal proteases

Cathepsin	Location	Family	Cleavage pattern	Phenotype/function
B	Lysosomes	Cysteine	Carboxypeptidase	Lysosomal apoptosis pathway and tumor spreading
C	Endo/lysosomes	Cysteine	Aminopeptidase	Serine protease activation
F	Lysosomes	Cysteine	Endopeptidase	Ii processing
K	Lysosomes	Cysteine	Endopeptidase	TLR9 signaling
L(V)	Lysosomes	Cysteine	Endopeptidase	CD4 and NK T cells tyimic selection
S	Endo/lysosomes	Cysteine	Endopeptidase	MHC class II pathway, Ii chain processing
X(Z)	Endo/lysosomes	Cysteine	Carboxypeptidase	T-cell migration
D,E	Lysosomes	Aspartic	Endopeptidase	Lysosomal storage, early cell death
AEP	Endo/lysosomes	Cysteine	Asparagine sites	MHC class II pathway, cathepsins maturation and TLR processing

endopeptidase (AEP) or legumain is unrelated to the papain-like cysteine protease family such as cathepsin B and L and is grouped together with the caspases, separases, and some bacterial proteases in clan CD [16–18]. Most of these enzymes are synthesized as precursors and targeted to the endocytic pathway. For example, the N- and C-terminal propeptides of AEP are auto-cleaved in the lysosomal compartments to generate a 46 kDa mature form, which can be further processed into a 36 kDa fragment [19].

Acidic pH is a prerequisite for maturation of most of these enzymes and so their greatest activity is found in lysosomal compartments. Their main function is to provide ligands for the MHC class II-restricted antigenic pathway. MHC class II molecules access the endolysosomal compartments to bind peptides and display them on the surface of DCs to trigger CD4⁺ T-cell response. Indeed, the uptake of exogenous antigen into DCs is followed by protease-mediated degradation in endolysosomal compartments. These proteases also process the invariant chain (Ii), a chaperone molecule which associates with MHC class II molecules in the endoplasmic reticulum (RE). Cathepsin L and cathepsin S are the best characterized proteases to proteolyse Ii [20]. The endolysosomal proteases have probably a redundant role in the selection of the peptides which will be presented at the DCs surface. However, there are examples where some antigens require a particular protease. Indeed, AEP is unique among lysosomal cysteine proteases, in that it is insensitive to leupeptin and cleaves on the carboxyl terminal sides of asparagine residues. AEP initiates the processing of tetanus toxin in human B cells, destroys an immuno-dominant peptide of myelin basic protein (MBP – an autoantigen implicated in the autoimmune disease multiple sclerosis) and performs the early steps of degradation of the Ii chain in human B-EBV cells [21–23].

3.2 Asparagine Endopeptidase, TLR7/9 Pathway and Antigen Presentation in DCs

DCs are heterogeneous and consist of various DC subsets among which TLR expression and function differ. pDC is a DC subset which differs from cDC and can produce vast amounts of type I interferon upon bacterial and viral infection. pDCs only express TLR7 and TLR9. Thus, pDCs can be regarded as a DC subset specialized for detecting nucleic acids mainly through TLR7/9. In mice, cross-presentation has been considered a unique property of cDCs. This crucial mechanism in microbial immunity allows exogenous antigen to be delivered into the MHC class I pathway to initiate cytotoxic T-cell response. However, recently, it has been shown that stimulation by TLR 7/9 also licences pDCs to cross-present [24].

Little is known about how endosomal TLRs and their ligands are targeted to the endocytic pathway. TLRs are sensitive to chloroquine, a lysomotropic agent that neutralizes acidic compartments indicating a role for endo/lysosomal proteases for their signaling. Indeed, recent findings have described the importance of proteolysis

for TLR9 function [25, 26]. It has recently been shown that mouse TLR9 is non-functional until it is subjected to proteolytic cleavage in the endosomes. Upon stimulation, full-length TLR9 is cleaved into a C-terminal fragment which is highly dependent on AEP in DCs. A recruitment of TLR9 and a boost in AEP activity, which was induced shortly after TLR9 stimulation, was shown to promote TLR9 cleavage and correlated with an increased acidification in endosomes and lysosomes. Moreover, mutating a putative AEP cleavage site in TLR9 strongly decreases its signaling in DCs suggesting perhaps that a direct cleavage of TLR9 by AEP is required for this process. These results demonstrated that TLR9 requires a proteolytic cleavage for its signaling and identified a key endocytic protease playing a critical role in this process in DCs [27]. Interestingly, in contrast, TLR9 processing does not rely on AEP in macrophages probably because of the already highly acidic milieu found in the endocytic pathway of macrophages in comparison to DCs, thus allowing many proteases (and not only AEP) such as cathepsins B, L, K and S to perform TLR9 degradation [25, 27] and thus, TLR9 proteolysis has been proposed to restrict receptor activation to endosomal/lysosomal compartments and to prevent TLRs from responding to selfnucleic acids. Other endosomal TLRs, and in particular TLR7, are also probably subjected to a similar proteolytic maturation but this remains to be fully investigated (unpublished data).

Several studies have suggested that intracellular TLRs can be targeted directly from the ER, where they reside, to endosomes in which they signal. Relatedly, mouse and human genomic studies have identified UNC93B1, which encodes for a 12-membrane spanning molecule highly conserved in the ER, as a key regulator in the transport of endosomal TLRs. The third mutation (UNC93B mutation) results in a phenotype where no signaling occurs via the intracellular TLRs 3, 7 and 9 and also diminishes presentation of exogenous antigen [28, 29]. However, the exact role played by UNC93B1 in these processes remains to be fully elucidated.

4 Proteases and Maladaptive Inflammation

Proteases produced by inflammatory cells such as neutrophils and macrophages play a crucial role in the first line of defense against invading bacteria, fungi and protozoa, either by directly killing pathogens or by inducing immune recognition, e.g., via TLRs. Individuals with cyclic neutropenia, a disease characterized by mutations in the gene encoding neutrophil elastase (NE), commonly experience recurrent bacterial infections, highlighting their critical importance in this respect. Neutrophils contain at least four types of granules: azurophil granules, specific granules, gelatinase granules, and secretory granules [30, 31]. In addition to proteases, these granules are an important reservoir of other antimicrobial proteins, such as defensins, and components of the respiratory burst oxidase [32]. It has also been suggested that these granules contain a wide range of membrane-bound receptors (e.g., CD11b/CD18 [33] and *N*-formyl-methionyl-leucyl-phenylalanine

[fMLP] receptor) for endothelial adhesion molecules, extracellular matrix proteins, bacterial products, and soluble mediators of inflammation [30, 32]. In addition to these molecules, a novel antimicrobial mechanism for neutrophils has recently been described, with the demonstration that neutrophils form neutrophil extracellular traps (NET) that could potentially bind, disarm and kill pathogens extracellularly [34–37]. DNA is the major structural component of NETs and it provides the backbone on which the proteinaceous effectors such as proteases are anchored to [34].

Although all of the effects described above are beneficial to the host, chronic and persistent presence of neutrophils is a hallmark of lung pathologies such as COPD and CF. There is certainly an excess of neutrophil chemoattractants such as IL-8 and leukotriene B₄ (LTB₄) recovered in bronchoalveolar lavage (BAL) fluid of these patients [38, 39]. Bacteria present in high concentrations in these pathologies also provide additional chemoattractants for neutrophils. Furthermore, neutrophils may survive longer in the airways of CF/COPD patients because of the production of excess concentrations of granulocyte macrophage-colony stimulating factor (GM-CSF) and the relative lack of IL-10, which, when present, promotes neutrophil apoptosis [38–41]. Moreover, cleavage of the phosphatidylserine receptor (PSR) and CD14 by NE could specifically disrupt phagocytosis of apoptotic neutrophils by macrophages [42, 43]. On the other hand, the decreased mucociliary clearance in CF/COPD leads to longer retention of apoptotic neutrophils causing them to necrose, hence releasing their toxic agents, e.g., NE, into the affected airways. In turn, NE contributes to the vicious circle of chronic inflammatory airway disease by inducing mucin production in airway epithelial cells [44–46]. Mucins, normally beneficial in microbial infections, by binding and removing bacteria via the mucociliary ladder, can be detrimental in chronic pathologies, by clogging the airways and providing an appropriate milieu for bacterial growth and colonization [47]. NE also reduces ciliary beat frequency resulting in marked disruption of epithelial cells [48], and induces goblet cell metaplasia which is dependent on its proteolytic activity [49–52].

In addition to the direct deleterious effect of proteases (such as NE) on innate immune effectors, these mediators also have a negative effect on immune cells such as DCs. For years, the nature of the elusive lung DCs was poorly understood, but with increasing interest in the role of adaptive immunity in the pathophysiology of human CF, COPD and emphysema, interest in further characterization of specific DC subsets in normal and diseased lungs arose [53–55]. In that context, we and others have shown that NE could be instrumental in the elicitation of this breach in host defense, through its action on DCs. Indeed, we demonstrated that NE is able to disable mature DC function by reducing the level of DC surface costimulatory molecules (CSMs), interfering both with the ability of immature DCs to mature in response to bacterial LPS and by reducing the allostimulatory activity of these cells, resulting in reduced Th1 cytokine production [56]. Similarly, neutrophils and culture supernatants of unprimed/primed neutrophils are able to downregulate human monocyte-derived DCs allostimulatory function *in vitro* [57]. This effect was associated with the amount of NE released by neutrophils, which in turn

converted immature myeloid DCs into transforming growth factor (TGF)- β 1-secreting cells [57]. These in vitro observations are further supported by an earlier report showing that APCs isolated from BAL fluid of CF patients were unable to present antigen and stimulate T-cell responses [58], despite appropriate responses from systemic APCs (monocytic cells). However, although the characteristics and functional properties of lung DCs can be easily studied in animal models, very few and in most cases contradictory data from their human counterparts are currently available [55].

4.1 Neutrophil Elastase

Human NE is a serine protease found in the azurophil granules of the neutrophil. The highly cationic glycoprotein product contains 218 amino acids and four disulfide bridges, and is a member of the serine protease family [59]. The catalytic site of the NE molecule is composed of the triad His41-Asp99-Ser173, in which the γ -oxygen of serine becomes a powerful nucleophile, able to attack a suitably located carbonyl group on the target substrate [60]. Neutrophils release NE upon exposure to various cytokines and chemoattractants, including tumor necrosis factor (TNF)- α , interleukin (IL)-8, C5a, LPS, and a tripeptide derived from bacterial wall fMLP [61]. The concentration of NE in neutrophils exceeds 5 mM [62], and each neutrophil contains approximately 400 NE-positive granules. Although NE is most abundant in neutrophils, small amounts are expressed by monocytes and T cells [63, 64]. NE has broad substrate specificity and is capable of degrading a wide range of extracellular matrix proteins, including elastin, collagen (types I–IV), fibronectin, laminin, and proteoglycans. Additionally, many biological molecules like cytokines and their receptors contain putative cleavage sites for neutrophil serine proteases. Indeed, as expected, many receptors, cytokines and other molecules have been found to be natural substrates for NE (Table 2).

Like the cysteine protease family described above, NE possesses potent microbicidal activity and is speculated to assist with phagocytosis of pathogens by activated neutrophils [65]. To determine the contribution of NE in combating bacterial infections, NE-deficient (NE^{-/-}) mice were generated [62] and shown to be more susceptible to sepsis and death following intraperitoneal infection with gram-negative (*Klebsiella pneumoniae*, *P. aeruginosa*, and *Escherichia coli*) but not gram-positive (*Staphylococcus aureus*) bacteria. NE is required for maximal intracellular killing of *P. aeruginosa* by neutrophils, as it degrades the major outer membrane protein F, a protein with important functions, including porin activity, maintenance of structural integrity, and sensing of host immune system activation [66]. In addition, in vitro incubation of NE with *E. coli* leads to a loss of bacterial integrity and lysis of bacteria [62]. Indeed, the primary sequence of outer membrane protein A (OmpA) amino acid has multiple NE-preferred cleavage sites and NE was shown to directly degrade purified OmpA of *E. coli* in vitro [62]. Furthermore, NE degrades virulence factors of enterobacteria such as *Salmonella enterica* serovar

Table 2 Summary of the expanding list of natural neutrophil elastase (NE) substrates

Target	Hypothetical biological function	References
Receptors		
Proteinase-activated receptor-1 (PAR-1)	Inactivation, modulation of response	[76, 150]
PAR-2	Inactivation, modulation of response	[150–152]
PAR-3	Inactivation, modulation of response	[153]
IL-2R α	Inhibiting cellular response and prolongation of cytokine half-life time	[154]
TNF-RII	Inhibiting cellular response and prolongation of cytokine half-life time	[155]
C5aR (CD88)	Inhibition of chemotaxis, feedback mechanism	[156]
CR1 (CD35)	Inhibition of complement signaling	[157]
Urokinase R (CD87)	Regulation of cell migration	[158]
Granulocyte-colony stimulating factor receptor (G-CSF-R)	Growth inhibition	[159, 160]
CD43 (sialophorin)	Regulation of adhesion	[161, 162]
CD14	Inhibition of LPS-mediated cell activation/apoptotic cell recognition	[163]
CD2, CD4, and CD8	Impairment of T lymphocytes	[164]
CD40, CD80, and CD86	Impairment of DCs	[56]
Soluble IL-6 receptor	Regulation of inflammation	[165]
CXC chemokine receptor 1 (CXCR1)	Regulation of cell migration	[166]
Cytokines/chemokines		
TNF- α	Regulation of inflammation	[167]
IL-2	Regulation of inflammation	[63]
IL-6	Regulation of inflammation	[168]
IL-8	Regulation of inflammation	[169]
IL-12p40	Regulation of inflammation	(unpublished)
G-CSF	Growth inhibition	[159]
Integrins/others		
Intercellular adhesion molecule-1 (ICAM-1)	Regulation of adhesion	[170, 171]
Vascular endothelium cadherin	Regulation of adhesion	[172]
Proepithelin	Regulation of wound healing	[173]
Tissue factor pathway inhibitor (TFPI)	Regulation of coagulation and intravascular thrombus growth	[174]
Matrix metalloprotease-9 (MMP-9)	Regulation of proteolysis	[175]
Tissue inhibitor of metalloprotease-1 (TIMP-1)	Regulation of proteolysis	[175]
Basic fibroblast growth factor (bFGF)	Regulation of angiogenesis	[176]
Vascular endothelial growth factor (VEGF)	Regulation of angiogenesis	[176, 177]
Laminin-332 (laminin-5)	Regulation of cell migration	[178]
Surfactant protein D (SP-D)		[179]

(continued)

Table 2 (continued)

Target	Hypothetical biological function	References
	Regulation of inflammation/innate immunity	
Insulin receptor substrate-1 (IRS-1)	Regulation of cell growth	[180]
von Willebrand factor (VWF)	Regulation of cell hemostasis	[181]
Cut homeobox 1 (CUX1)	Regulation of gene expression	[182]
Plasma factor XIII (FXIII)	Regulation of coagulation	[183]
AlphaIIb β 3	Regulation of adhesion	[184]

Typhimurium, *Shigella flexneri*, *Yersinia enterocolitica* and *Streptococcus pneumoniae* [67]. Thus, in the absence of NE these bacteria escape from the phagolysosome leading to their increased survival in the cytoplasm of infected neutrophils [68]. Finally, NE is able to suppress flagellin transcription in *P. aeruginosa*. Flagellin suppression by NE could elucidate how and why CF patients undergo cyclical exacerbations of the inflammatory lung disease caused by *P. aeruginosa*. When neutrophil numbers and thus NE concentrations are low, *P. aeruginosa* may proliferate, assemble a flagellum, and release flagellin, stimulating a robust inflammatory response in the patient’s airways [69].

4.1.1 NE Signaling Activity

It has been suggested that NE signals via the cell surface membrane-bound TLR4 [70], by activating the NF- κ B signaling pathway [71–73]. A more recent study, however, proposed that IL-1R1/MyD88 signaling and inflammasome activation, but not TLRs, are critical for NE-induced lung inflammation and emphysema in murine models [74]. Additionally, NE has been reported to induce apoptosis, thus contributing to the pathogenesis of inflammatory injury in the respiratory tract. NE-induced apoptosis of lung epithelial cells is mediated by a proteinase-activated receptor-1 (PAR1)-triggered pathway involving activation of NF- κ B and p53, and a PUMA- and Bax-dependent increase in mitochondrial permeability leading to activation of distal caspases [75, 76].

4.2 Endogenous Protease Inhibitors

To modulate the multiple activities of proteases (including NE), either beneficial, but also potentially deleterious (see above), the body synthesizes antiproteases. We will concentrate our discussion on NE inhibitors, as other inhibitors will be described in this issue by other contributors. These NE inhibitors can be broadly classified into two groups, the “alarm” and the “systemic” antiproteases. Systemic antiproteases, such as α 1-protease inhibitor (α 1-PI), are produced mainly by hepatocytes. However, during infection, the activity of locally produced mucosal

alarm antiproteases such as SLPI and elafin may add an extra edge to the host defense armamentarium, as will be discussed below (reviewed in [77] and [78]).

4.2.1 Alarm Antiproteases

SLPI and elafin alarm *antiproteases* have been isolated and characterized under a variety of names in adult and fetal tissues [78]. They belong to the family of whey-acidic protein (WAP) proteins and are produced by epithelial cells and cells of the immune system. Importantly, alarm antiproteases are generated locally in areas of infection or neutrophil infiltration and are upregulated by pathogen- and inflammation-associated factors, including cytokines and NE itself [79]. In addition to their antiprotease properties, and because of their biochemical characteristics (heavily disulphide-bonded, low molecular mass cationic peptides, present at mucosal sites), elafin and SLPI have recently been proposed to possess “defensin/cathelicidin-like” properties [77, 78, 80].

Elafin

Elafin was simultaneously isolated from the skin of psoriatic patients [81, 82] and from the sputum of COPD subjects [83, 84]. Elafin gene was cloned and sequenced by Saheki and colleagues in 1992 [85] and by Sallenave and Silva in 1993 [86], and shown to code for a 117-amino acids protein, of which the first 22 amino acids represent a hydrophobic signal peptide. Elafin is produced as a 9.9-kDa full-length non-glycosylated cationic protein composed of an N-terminal “cementoin” domain which facilitates transglutaminase-mediated cross-linkage on to polymers or extracellular matrix components and a globular C-terminus, containing the protease inhibitor moiety [87]. The elafin molecule shares ~40% homology with SLPI and has been shown to be a more specific inhibitor of proteases than SLPI, since it inhibits NE, porcine pancreatic enzyme, and proteinase 3 [83, 88, 89], but does not inhibit cathepsin G, trypsin, or chymotrypsin [83, 88].

The regulation of elafin expression during inflammation has been well studied. In vitro, bronchial and alveolar epithelial cells produce little elafin protein, but the quantity of elafin recovered from the supernatant can be greatly enhanced by addition of the inflammatory cytokines IL-1 and TNF- α [79]. These cytokines induce similar increases in expression of elafin from keratinocytes in vitro [90]. The c-jun, p38 mitogen-activated protein (MAP) kinase, and NF- κ B pathways are thought to be implicated in the elafin response to inflammatory cytokines [91–93]. Of note, the cytokine-mediated increase in elafin production by epithelial cells is greater than the increase in SLPI production [79]. Hence, whereas SLPI has been described as providing a baseline antiprotease shield and can be isolated from bronchial lavage samples from healthy individuals [94–96], elafin might be of greater significance during an inflammatory challenge to the lungs. In keeping

with this notion, elafin mRNA expression in bronchial epithelial cells is increased by free NE, which is found in abundance at times of inflammation [97, 98].

Although inhibition of NE activity has historically been considered to be the primary role of elafin, recent work has highlighted further properties of this cationic molecule. Simpson and colleagues [99] demonstrated that elafin has antibacterial activity against gram-negative *P. aeruginosa* and gram-positive *S. aureus*, and further established that, while antiprotease activity resides exclusively in the C-terminus, the majority of antimicrobial activity of elafin resides in its N-terminal domain [99]. In support of these findings, supernatants of *P. aeruginosa* could induce elafin production in human keratinocytes, and elafin inhibits growth of *P. aeruginosa* in vitro, but not *E. coli* [100, 101]. Further, adenovirus (Ad)-mediated augmentation of human elafin in murine lungs was shown to protect the lungs against *P. aeruginosa*-mediated injury, and also reduced bacterial numbers. Similarly, overexpression of elafin using the Ad-strategy dramatically improved the clearance of *S. aureus* in vitro and in vivo [102]. In these studies, concomitant anti-inflammatory activities have been demonstrated, which can probably be explained by an inhibition of the AP-1 and NF- κ B pathways [103, 104]. More recently, using wild-type and CD14 knockout mice, Wilkinson and co-workers demonstrated the opsonic activity for elafin against *P. aeruginosa*, both in vitro and in vivo [105]. In an extension of these data, there is evidence that elafin binds both smooth and rough forms of LPS in vitro and could potentially modulate immune responses depending on the microenvironment [106].

We have also shown that elafin exhibits chemotactic activity for leukocytes locally in the lung [107, 108], while, conversely, downregulating inflammation systemically [108]. In keeping with this immunomodulatory activity, we demonstrated that overexpression of elafin in murine lungs results in a higher number of CD11c⁺/MHCII⁺ DCs with an activated phenotype, as evidenced by expression of higher levels of co-stimulatory molecules CSMs (CD80 and CD86), and higher levels of Th1-biased cytokines IL-12p40, TNF- α , and IFN- γ in their bronchoalveolar (BAL) fluids [109].

Secretory Leukocyte Protease Inhibitor

Secretory leukocyte protease inhibitor (SLPI) is an 11.7-kDa protein that was first isolated from human parotid gland secretions [110]. SLPI orthologs have also been demonstrated in mice, rats, pigs, and sheep [111–113]. It is a non-glycosylated, highly basic, acid-stable, cysteine-rich, 107-amino acid, single-chain polypeptide [110]. The tertiary structure of the SLPI molecule resembles a boomerang, with each arm carrying one domain [114]. The four-in-each-domain disulfide bridges formed between the cysteine residues, as well as the two-domain interaction, contribute to the conformation and efficacy of the molecule [115]. SLPI provides a significant component of the human antiprotease shield within the lung. Through its C-terminal domain, SLPI gives significant protection against proteases, such as NE and the serine protease cathepsin G [116]. SLPI is produced by various

inflammatory cells, such as neutrophils [117], mast cells [118], and macrophages [119]. It is estimated that SLPI is present at concentrations of 0.1–2 $\mu\text{g/ml}$ in BAL fluid [120, 121] and 2.5 $\mu\text{g/ml}$ in nasal secretions [122].

It is believed that SLPI also shields the tissues against inflammatory products by downregulating the macrophage responses against bacterial LPS. Patients with sepsis have elevated circulating SLPI levels and LPS is the key mediator in bacterial endotoxic shock [96, 123, 124]. LPS seems to induce SLPI production by macrophages directly or by way of IL-1 β , TNF- α , IL-6, and IL-10 [125, 126]. SLPI, like elafin, in turn inhibits the downstream components of the NF- κ B pathway by protecting the inhibitor of NF- κ (I- κ B) from degradation by the ubiquitin-proteasome pathway [103]. SLPI is believed to enter cells, becoming rapidly localized to the cytoplasm and nucleus where it affects NF- κ B activation by binding directly to NF- κ B binding sites in a site-specific manner [127]. Thus, SLPI renders macrophages unable to release pro-inflammatory cytokines and nitric oxide [125]. These data have been confirmed by *in vivo* studies demonstrating that SLPI knockout mice show increased susceptibility to endotoxic shock, and macrophages and B lymphocytes from the same mice show increased activation after administration of LPS [128].

In addition to its NE inhibitory and immunomodulatory activities, SLPI, like elafin, possesses broad-spectrum antibactericidal, antiviral, and antifungal properties [115, 129–134].

The Systemic Antiprotease α 1-Protease Inhibitor

The systemic antiprotease α 1-PI (also called α 1-antitrypsin) is a 52-kDa secreted glycoprotein and is the prototypic member of the serine protease inhibitor (serpin) superfamily of proteins, which has a major role in inactivating NE and other proteases, such as cathepsin G and proteinase 3. Although some epithelial surfaces and cells of the immune system may produce small quantities of systemic antiproteases, such as α 1-PI [135, 136], these inhibitors are produced primarily by hepatocytes [137, 138]. The production of α 1-PI by alveolar macrophages is upregulated by pro-inflammatory cytokines and bacterial LPS [139]. Also, the cytokine oncostatin M is a major inducer of α 1-PI in bronchial epithelial cells [135, 140].

The importance of α 1-PI in the lung has historically been inferred from genetic studies: α 1-PI deficiency is a genetic disorder that affects about 1 in 2,000–5,000 individuals. α 1-PI deficiency is characterized by a decrease in levels of secreted α 1-PI, which results in early-onset of emphysema in affected individuals. Although it was originally believed that genetic emphysema was caused by this decreased secretion of α 1-PI in the respiratory tract, leading to unopposed and prolonged NE activity [141], recent evidence suggests that the mutated Z variant of α 1-PI, when polymerized, may be pro-inflammatory when secreted, acting as an important chemoattractant for neutrophils in the α 1-PI-deficient lung and adding to the excessive neutrophil and NE burden [137, 142].

In addition to its role as an antiprotease, like elafin and SLPI, α 1-PI possesses important pleiotropic anti- or pro-inflammatory properties, depending upon the conditions. These effects include blocking of the pro-inflammatory effects of human NE [143, 144], and regulating expression of pro-inflammatory cytokines such as TNF- α , IL-6, IL-8, IL-1 β , and monocyte chemotactic protein (MCP)-1 by monocytes [145, 146]. Both the native and polymerized forms of α 1-PI have been shown to possess similar effects as monocyte stimulators, with pro-inflammatory effects at low doses, and anti-inflammatory activities at physiologically normal doses [145]. This strengthens the concept that some of the apparently contradictory effects of these inhibitors reported in the literature may be due to differences in dosage between experimental protocols.

Lastly, α 1-PI could also inhibit alveolar cell apoptosis in vivo [147]. Thus direct inhibition of active NE [75] and caspase-3 [148] by α 1-PI may represent a novel anti-apoptotic mechanism relevant to disease processes characterized by excessive structural cell apoptosis, oxidative stress, and inflammation in the airways [149].

5 Conclusions

Here, we have described the important role of proteases in immune functions, not only in the direct degradation of micro-organisms and antigen presentation, but also in the induction of inflammatory responses. We have also discussed the importance of protease inhibitors in the modulation of maladaptive responses caused by extracellularly released proteases. Finally, we described novel bioactivities of elastase inhibitors, such as antimicrobial and adjuvant-like functions. These latter functions are likely to be exploited further for the treatment of individuals prone to developing CF and COPD, especially to combat frequent episodes of lung infections, either in a therapeutic (antimicrobial activity) or prophylactic (vaccination) fashion.

References

1. Rawlings ND, Morton FR, Barrett AJ (2006) MEROPS: the peptidase database. *Nucleic Acids Res* 34:D270–D272
2. Pardo A, Selman M, Kaminski N (2008) Approaching the degradome in idiopathic pulmonary fibrosis. *Int J Biochem Cell Biol* 40:1141–1155
3. Anderson KV (2000) Toll signaling pathways in the innate immune response. *Curr Opin Immunol* 12:13–19
4. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. *Int Immunol* 17:1–14
5. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. *Immunity* 11:443–451

6. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature* 410:1099–1103
7. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H (2000) Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. *J Exp Med* 192:595–600
8. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 303:1529–1531
9. Janeway CA Jr (2002) A trip through my life with an immunological theme. *Annu Rev Immunol* 20:1–28
10. Kumagai Y, Takeuchi O, Akira S (2008) TLR9 as a key receptor for the recognition of DNA. *Adv Drug Deliv Rev* 60:795–804
11. Abou Fakher FH, Rachinel N, Klimczak M, Louis J, Doyen N (2009) TLR9-dependent activation of dendritic cells by DNA from *Leishmania major* favors Th1 cell development and the resolution of lesions. *J Immunol* 182:1386–1396
12. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K et al (2000) A Toll-like receptor recognizes bacterial DNA. *Nature* 408:740–745
13. Magnusson M, Tobes R, Sancho J, Pareja E (2007) Cutting edge: natural DNA repetitive extragenic sequences from gram-negative pathogens strongly stimulate TLR9. *J Immunol* 179:31–35
14. Huang X, Barrett RP, McClellan SA, Hazlett LD (2005) Silencing Toll-like receptor-9 in *Pseudomonas aeruginosa* keratitis. *Invest Ophthalmol Vis Sci* 46:4209–4216
15. Blum JS, Cresswell P (1988) Role for intracellular proteases in the processing and transport of class II HLA antigens. *Proc Natl Acad Sci USA* 85:3975–3979
16. Chen JM, Dando PM, Rawlings ND, Brown MA, Young NE, Stevens RA, Hewitt E, Watts C, Barrett AJ (1997) Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. *J Biol Chem* 272:8090–8098
17. Chen JM, Dando PM, Stevens RA, Fortunato M, Barrett AJ (1998) Cloning and expression of mouse legumain, a lysosomal endopeptidase. *Biochem J* 335(Pt 1):111–117
18. Uhlmann F, Wernic D, Poupard MA, Koonin EV, Nasmyth K (2000) Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. *Cell* 103:375–386
19. Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C (2003) Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. *J Biol Chem* 278:38980–38990
20. Chapman HA (2006) Endosomal proteases in antigen presentation. *Curr Opin Immunol* 18:78–84
21. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C (1998) An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. *Nature* 396:695–699
22. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, Mazza G, Wraith DC, Watts C (2002) Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. *Nat Immunol* 3:169–174
23. Manoury B, Mazzeo D, Li DN, Billson J, Loak K, Benaroch P, Watts C (2003) Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. *Immunity* 18:489–498
24. Mouries J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C (2008) Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. *Blood* 112:3713–3722
25. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL (2008) Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. *Nat Immunol* 9:1407–1414
26. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, Barton GM (2008) The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. *Nature* 456:658–662

27. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E, Lennon-Dumenil AM, Amigorena S, Cabanie L, Manoury B (2009) Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. *Immunity* 31:737–748
28. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, Mudd S, Mann N, Sovath S, Goode J et al (2006) The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. *Nat Immunol* 7:156–164
29. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL (2008) UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. *Nature* 452:234–238
30. Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. *Blood* 89:3503–3521
31. Faurschou M, Borregaard N (2003) Neutrophil granules and secretory vesicles in inflammation. *Microbes Infect* 5:1317–1327
32. Hager M, Cowland JB, Borregaard N (2010) Neutrophil granules in health and disease. *J Intern Med* 268:25–34
33. Calafat J, Kuijpers TW, Janssen H, Borregaard N, Verhoeven AJ, Roos D (1993) Evidence for small intracellular vesicles in human blood phagocytes containing cytochrome b558 and the adhesion molecule CD11b/CD18. *Blood* 81:3122–3129
34. Balloy V, Sallenave JM, Crestani B, Dehoux M, Chignard M (2003) Neutrophil DNA contributes to the antielastase barrier during acute lung inflammation. *Am J Respir Cell Mol Biol* 28:746–753
35. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. *Science* 303:1532–1535
36. Medina E (2009) Neutrophil extracellular traps: a strategic tactic to defeat pathogens with potential consequences for the host. *J Innate Immun* 1:176–180
37. Papayannopoulos V, Zychlinsky A (2009) NETs: a new strategy for using old weapons. *Trends Immunol* 30:513–521
38. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M (1995) Inflammatory cytokines in cystic fibrosis lungs. *Am J Respir Crit Care Med* 152:2111–2118
39. Barnes PJ, Shapiro SD, Pauwels RA (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J* 22:672–688
40. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD (1997) Lower airway inflammation in infants and young children with cystic fibrosis. *Am J Respir Crit Care Med* 156:1197–1204
41. Bonfield TL, Konstan MW, Berger M (1999) Altered respiratory epithelial cell cytokine production in cystic fibrosis. *J Allerg Clin Immunol* 104:72–78
42. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM (2002) Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. *J Clin Invest* 109:661–670
43. Henriksen PA, Devitt A, Kotelevtsev Y, Sallenave JM (2004) Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. *FEBS Lett* 574:80–84
44. Voynow JA, Gendler SJ, Rose MC (2006) Regulation of mucin genes in chronic inflammatory airway diseases. *Am J Respir Cell Mol Biol* 34:661–665
45. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM (1999) Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. *Am J Physiol* 276:L835–843
46. Kohri K, Ueki IF, Nadel JA (2002) Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. *Am J Physiol Lung Cell Mol Physiol* 283:L531–540
47. Rose MC, Voynow JA (2006) Respiratory tract mucin genes and mucin glycoproteins in health and disease. *Physiol Rev* 86:245–278

48. Amitani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, Stockley RA, Cole PJ (1991) Effects of human neutrophil elastase and *Pseudomonas aeruginosa* proteinases on human respiratory epithelium. *Am J Respir Cell Mol Biol* 4:26–32
49. Lucey EC, Stone PJ, Breuer R, Christensen TG, Calore JD, Catanese A, Franzblau C, Snider GL (1985) Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with in vitro observations on elastolysis by these enzymes. *Am Rev Respir Dis* 132:362–366
50. Breuer R, Christensen TG, Lucey EC, Stone PJ, Snider GL (1985) Quantitative study of secretory cell metaplasia induced by human neutrophil elastase in the large bronchi of hamsters. *J Lab Clin Med* 105:635–640
51. Voynow JA, Fischer BM, Malarkey DE, Burch LH, Wong T, Longphre M, Ho SB, Foster WM (2004) Neutrophil elastase induces mucus cell metaplasia in mouse lung. *Am J Physiol Lung Cell Mol Physiol* 287:L1293–1302
52. Voynow JA, Rubin BK (2009) Mucins, mucus, and sputum. *Chest* 135:505–512
53. von Garnier C, Filgueira L, Wikstrom M, Smith M, Thomas JA, Strickland DH, Holt PG, Stumbles PA (2005) Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. *J Immunol* 175:1609–1618
54. Vermaelen K, Pauwels R (2005) Pulmonary dendritic cells. *Am J Respir Crit Care Med* 172:530–551
55. Tsoumakidou M, Demedts IK, Brusselle GG, Jeffery PK (2008) Dendritic cells in chronic obstructive pulmonary disease: new players in an old game. *Am J Respir Crit Care Med* 177:1180–1186
56. Roghanian A, Drost EM, MacNee W, Howie SE, Sallenave JM (2006) Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. *Am J Respir Crit Care Med* 174:1189–1198
57. Maffia PC, Zittermann SE, Scimone ML, Tateosian N, Amiano N, Guerrieri D, Lutzky V, Rosso D, Romeo HE, Garcia VE et al (2007) Neutrophil elastase converts human immature dendritic cells into transforming growth factor-beta1-secreting cells and reduces allostimulatory ability. *Am J Pathol* 171:928–937
58. Knight AM, Lucocq JM, Prescott AR, Ponnambalam S, Watts C (1997) Antigen endocytosis and presentation mediated by human membrane IgG1 in the absence of the Ig(alpha)/Ig(beta) dimer. *EMBO J* 16:3842–3850
59. Bode W, Meyer E Jr, Powers JC (1989) Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. *Biochemistry* 28:1951–1963
60. Kelly E, Greene CM, McElvaney NG (2008) Targeting neutrophil elastase in cystic fibrosis. *Expert Opin Ther Targets* 12:145–157
61. Lee WL, Downey GP (2001) Leukocyte elastase: physiological functions and role in acute lung injury. *Am J Respir Crit Care Med* 164:896–904
62. Belaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, Shapiro SD (1998) Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. *Nat Med* 4:615–618
63. Ariel A, Yavin EJ, Hershkovitz R, Avron A, Franitza S, Hardan I, Cahalon L, Fridkin M, Lider O (1998) IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. *J Immunol* 161:2465–2472
64. Shapiro SD (1994) Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. *Am J Respir Crit Care Med* 150: S160–S164
65. Reeves EP, Lu H, Jacobs HL, Messina CG, Bolsover S, Gabella G, Potma EO, Warley A, Roes J, Segal AW (2002) Killing activity of neutrophils is mediated through activation of proteases by K⁺ flux. *Nature* 416:291–297

66. Hirche TO, Benabid R, Deslee G, Gangloff S, Achilefu S, Guenounou M, Lebargy F, Hancock RE, Belaouaj A (2008) Neutrophil elastase mediates innate host protection against *Pseudomonas aeruginosa*. *J Immunol* 181:4945–4954
67. Standish AJ, Weiser JN (2009) Human neutrophils kill *Streptococcus pneumoniae* via serine proteases. *J Immunol* 183:2602–2609
68. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A (2002) Neutrophil elastase targets virulence factors of enterobacteria. *Nature* 417:91–94
69. Sonawane A, Jyot J, During R, Ramphal R (2006) Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in *Pseudomonas aeruginosa*. *Infect Immun* 74:6682–6689
70. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG (2003) Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. *FEBS Lett* 544:129–132
71. Geraghty P, Rogan MP, Greene CM, Boxio RM, Poiriert T, O'Mahony M, Belaouaj A, O'Neill SJ, Taggart CC, McElvaney NG (2007) Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. *J Immunol* 178:5871–5878
72. Lee KY, Ho SC, Lin HC, Lin SM, Liu CY, Huang CD, Wang CH, Chung KF, Kuo HP (2006) Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway. *Am J Respir Cell Mol Biol* 35:407–414
73. Walsh DE, Greene CM, Carroll TP, Taggart CC, Gallagher PM, O'Neill SJ, McElvaney NG (2001) Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. *J Biol Chem* 276:35494–35499
74. Couillin I, Vasseur V, Charron S, Gasse P, Tavernier M, Guillet J, Lagente V, Fick L, Jacobs M, Coelho FR et al (2009) IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. *J Immunol* 183:8195–8202
75. Suzuki T, Yamashita C, Zemans RL, Briones N, Van Linden A, Downey GP (2009) Leukocyte elastase induces lung epithelial apoptosis via a PAR-1-, NF-kappaB-, and p53-dependent pathway. *Am J Respir Cell Mol Biol* 41:742–755
76. Renesto P, Si-Tahar M, Moniatte M, Balloy V, Van Dorsselaer A, Pidard D, Chignard M (1997) Specific inhibition of thrombin-induced cell activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor. *Blood* 89:1944–1953
77. Roghanian A, Sallenave JM (2008) Neutrophil elastase (NE) and NE inhibitors: canonical and noncanonical functions in lung chronic inflammatory diseases (cystic fibrosis and chronic obstructive pulmonary disease). *J Aerosol Med Pulm Drug Deliv* 21:125–144
78. Sallenave JM (2010) Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. *Am J Respir Cell Mol Biol* 42:635–643
79. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gaudie J (1994) Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. *Am J Respir Cell Mol Biol* 11:733–741
80. Williams SE, Brown TI, Roghanian A, Sallenave JM (2006) SLPI and elafin: one glove, many fingers. *Clin Sci (Lond)* 110:21–35
81. Wiedow O, Luademann J, Utecht B (1991) Elafin is a potent inhibitor of proteinase 3. *Biochem Biophys Res Commun* 174:6–10
82. Schalkwijk J, van Vlijmen IM, Alkemade JA, de Jongh GJ (1993) Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. *J Invest Dermatol* 100:390–393
83. Sallenave JM, Ryle AP (1991) Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. *Biol Chem Hoppe Seyler* 372:13–21
84. Sallenave JM, Marsden MD, Ryle AP (1992) Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. *Biol Chem Hoppe Seyler* 373:27–33

85. Saheki T, Ito F, Hagiwara H, Saito Y, Kuroki J, Tachibana S, Hirose S (1992) Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. *Biochem Biophys Res Commun* 185:240–245
86. Sallenave JM, Silva A (1993) Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. *Am J Respir Cell Mol Biol* 8:439–445
87. Nara K, Ito S, Ito T, Suzuki Y, Ghoneim MA, Tachibana S, Hirose S (1994) Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed “cementoin”. *J Biochem* 115:441–448
88. Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E (1990) Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. *J Biol Chem* 265:14791–14795
89. Ying QL, Simon SR (2001) Kinetics of the inhibition of proteinase 3 by elafin. *Am J Respir Cell Mol Biol* 24:83–89
90. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S (2000) Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. *Br J Dermatol* 143:728–732
91. Pfundt R, van Vlijmen-Willems I, Bergers M, Wingens M, Cloin W, Schalkwijk J (2001) In situ demonstration of phosphorylated c-jun and p38 MAP kinase in epidermal keratinocytes following ultraviolet B irradiation of human skin. *J Pathol* 193:248–255
92. Pfundt R, Wingens M, Bergers M, Zweers M, Frenken M, Schalkwijk J (2000) TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. *Arch Dermatol Res* 292:180–187
93. Bingle L, Tetley TD, Bingle CD (2001) Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. *Am J Respir Cell Mol Biol* 25:84–91
94. Van Seuningen I, Audie JP, Gosselin B, Lafitte JJ, Davril M (1995) Expression of human mucous proteinase inhibitor in respiratory tract: a study by in situ hybridization. *J Histochem Cytochem* 43:645–648
95. Tremblay GM, Sallenave JM, Israel-Assayag E, Cormier Y, Gauldie J (1996) Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. *Am J Respir Crit Care Med* 154:1092–1098
96. Sallenave JM, Donnelly SC, Grant IS, Robertson C, Gauldie J, Haslett C (1999) Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. *Eur Respir J* 13:1029–1036
97. Reid PT, Marsden ME, Cunningham GA, Haslett C, Sallenave JM (1999) Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. *FEBS Lett* 457:33–37
98. van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, Hiemstra PS (2000) Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. *Am J Physiol Lung Cell Mol Physiol* 278:L51–58
99. Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM (1999) Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. *FEBS Lett* 452:309–313
100. Meyer-Hoffert U, Wichmann N, Schwichtenberg L, White PC, Wiedow O (2003) Supernatants of *Pseudomonas aeruginosa* induce the *Pseudomonas*-specific antibiotic elafin in human keratinocytes. *Exp Dermatol* 12:418–425
101. Bellemare A, Vernoux N, Morisset D, Bourbonnais Y (2008) Human pre-elafin inhibits a *Pseudomonas aeruginosa*-secreted peptidase and prevents its proliferation in complex media. *Antimicrob Agents Chemother* 52:483–490
102. McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR, Dorin JR, Sallenave JM (2005) Antimicrobial activity of murine lung cells against *Staphylococcus aureus* is increased in vitro and in vivo after elafin gene transfer. *Infect Immun* 73:3609–3617

103. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM (2004) Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. *J Immunol* 172:4535–4544
104. Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG (2006) Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. *J Biol Chem* 281:34730–34735
105. Wilkinson TS, Dhaliwal K, Hamilton TW, Lipka AF, Farrell L, Davidson DJ, Duffin R, Morris AC, Haslett C, Govan JR et al (2009) Trappin-2 promotes early clearance of *Pseudomonas aeruginosa* through CD14-dependent macrophage activation and neutrophil recruitment. *Am J Pathol* 174:1338–1346
106. McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM (2005) The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. *Am J Respir Cell Mol Biol* 32:443–452
107. Simpson AJ, Cunningham GA, Porteous DJ, Haslett C, Sallenave JM (2001) Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. *Hum Gene Ther* 12:1395–1406
108. Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C (2003) Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. *Infect Immun* 71:3766–3774
109. Roghanian A, Williams SE, Sheldrake TA, Brown TI, Oberheim K, Xing Z, Howie SE, Sallenave JM (2006) The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity. *Am J Respir Cell Mol Biol* 34:634–642
110. Thompson RC, Ohlsson K (1986) Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. *Proc Natl Acad Sci USA* 83:6692–6696
111. Zitnik RJ, Zhang J, Kashem MA, Kohno T, Lyons DE, Wright CD, Rosen E, Goldberg I, Hayday AC (1997) The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. *Biochem Biophys Res Commun* 232:687–697
112. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, Billingham RC, Poole AR, Wahl SM (1999) Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. *J Exp Med* 190:535–542
113. Brown TI, Mistry R, Gray R, Imrie M, Collie DD, Sallenave JM (2005) Characterization of the ovine ortholog of secretory leukoprotease inhibitor. *Mamm Genome* 16:621–630
114. Grutter MG, Fendrich G, Huber R, Bode W (1988) The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. *EMBO J* 7:345–351
115. Hiemstra PS, Maassen RJ, Stolk J, Heinzl-Wieland R, Steffens GJ, Dijkman JH (1996) Antibacterial activity of antileukoprotease. *Infect Immun* 64:4520–4524
116. Gauthier F, Fryksmark U, Ohlsson K, Bieth JG (1982) Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor. *Biochim Biophys Acta* 700:178–183
117. Sallenave JM, Si Tahar M, Cox G, Chignard M, Gaudie J (1997) Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. *J Leukoc Biol* 61:695–702
118. Westin U, Lundberg E, Wihl JA, Ohlsson K (1999) The effect of immediate-hypersensitivity reactions on the level of SLPI, granulocyte elastase, alpha1-antitrypsin, and albumin in nasal secretions, by the method of unilateral antigen challenge. *Allergy* 54:857–864
119. Mihaila A, Tremblay GM (2001) Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. *Z Naturforsch C* 56:291–297
120. Vogelmeier C, Biedermann T, Maier K, Mazur G, Behr J, Krombach F, Buhl R (1997) Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative stress. *Eur Respir J* 10:2114–2119

121. Kouchi I, Yasuoka S, Ueda Y, Ogura T (1993) Analysis of secretory leukocyte protease inhibitor (SLPI) in bronchial secretions from patients with hypersecretory respiratory diseases. *Tokushima J Exp Med* 40:95–107
122. Lee CH, Igarashi Y, Hohman RJ, Kaulbach H, White MV, Kaliner MA (1993) Distribution of secretory leukoprotease inhibitor in the human nasal airway. *Am Rev Respir Dis* 147:710–716
123. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, Wright CD, Weyant MJ, Hydo L, Reeves F et al (2000) Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. *Crit Care Med* 28:1276–1282
124. Duits LA, Tjabringa GS, Aarts NJ, Hiemstra PS, Nibbering PH, van Dissel JT, Van't Wout JW (2003) Plasma secretory leukocyte protease inhibitor in febrile patients. *Clin Microbiol Infect* 9:605–613
125. Jin FY, Nathan C, Radzioch D, Ding A (1997) Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. *Cell* 88:417–426
126. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, Sarma V, Gibbs DF, Tefera W, McConnell PC et al (1999) Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. *J Immunol* 162:3653–3662
127. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O'Neill SJ, McElvaney NG (2005) Secretory leukoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. *J Exp Med* 202:1659–1668
128. Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, Igarashi T, Ebina M, Abe T, Miyazaki J et al (2003) Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. *J Exp Med* 197:669–674
129. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM (1995) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. *J Clin Invest* 96:456–464
130. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. *Blood* 90:1141–1149
131. Tomee JF, Hiemstra PS, Heinzel-Wieland R, Kauffman HF (1997) Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. *J Infect Dis* 176:740–747
132. Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine MD, Belec L (2000) Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. *Clin Diagn Lab Immunol* 7:515–518
133. King AE, Critchley HO, Kelly RW (2003) Innate immune defences in the human endometrium. *Reprod Biol Endocrinol* 1:116
134. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC (2004) Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. *Infect Immun* 72:1956–1963
135. Sallenave JM, Tremblay GM, Gaudie J, Richards CD (1997) Oncostatin M, but not interleukin-6 or leukemia inhibitory factor, stimulates expression of alpha1-proteinase inhibitor in A549 human alveolar epithelial cells. *J Interferon Cytokine Res* 17:337–346
136. Paakko P, Kirby M, du Bois RM, Gillissen A, Ferrans VJ, Crystal RG (1996) Activated neutrophils secrete stored alpha 1-antitrypsin. *Am J Respir Crit Care Med* 154:1829–1833
137. Lomas DA, Mahadeva R (2002) Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. *J Clin Invest* 110:1585–1590
138. Stecenko AA, Brigham KL (2003) Gene therapy progress and prospects: alpha-1 antitrypsin. *Gene Ther* 10:95–99
139. Chughtai B, O'Riordan TG (2004) Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. *J Aerosol Med* 17:289–298

140. Boutten A, Venembre P, Seta N, Hamelin J, Aubier M, Durand G, Dehoux MS (1998) Oncostatin M is a potent stimulator of alpha1-antitrypsin secretion in lung epithelial cells: modulation by transforming growth factor-beta and interferon-gamma. *Am J Respir Cell Mol Biol* 18:511–520
141. Campbell EJ, Campbell MA, Boukedes SS, Owen CA (1999) Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. *J Clin Invest* 104:337–344
142. Parmar JS, Mahadeva R, Reed BJ, Farahi N, Cadwallader KA, Keogan MT, Bilton D, Chilvers ER, Lomas DA (2002) Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. *Am J Respir Cell Mol Biol* 26:723–730
143. Stockley RA, Bayley DL, Unsal I, Dowson LJ (2002) The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. *Am J Respir Crit Care Med* 165:1494–1498
144. Spencer LT, Paone G, Krein PM, Rouhani FN, Rivera-Nieves J, Brantly ML (2004) Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. *Am J Physiol Lung Cell Mol Physiol* 286:L514–520
145. Aldonyte R, Jansson L, Janciauskiene S (2004) Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro. *BMC Cell Biol* 5:11
146. Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T (2004) Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. *Biochem Biophys Res Commun* 321:592–600
147. Petrache I, Fijalkowska I, Medler TR, Skirball J, Cruz P, Zhen L, Petrache HI, Flotte TR, Tudor RM (2006) Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. *Am J Pathol* 169:1155–1166
148. Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L et al (2006) A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. *Am J Respir Crit Care Med* 173:1222–1228
149. Modrykamien A, Stoller JK (2009) Alpha-1 antitrypsin (AAT) deficiency – what are the treatment options? *Expert Opin Pharmacother* 10:2653–2661
150. Loew D, Perrault C, Morales M, Moog S, Ravanat C, Schuhler S, Arcone R, Pietropaolo C, Cazenave JP, van Dorsselaer A et al (2000) Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. *Biochemistry* 39:10812–10822
151. Dulon S, Cande C, Bunnett NW, Hollenberg MD, Chignard M, Pidard D (2003) Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. *Am J Respir Cell Mol Biol* 28:339–346
152. Dulon S, Leduc D, Cottrell GS, D'Alayer J, Hansen KK, Bunnett NW, Hollenberg MD, Pidard D, Chignard M (2005) *Pseudomonas aeruginosa* elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. *Am J Respir Cell Mol Biol* 32:411–419
153. Cumashi A, Ansuini H, Celli N, De Blasi A, O'Brien PJ, Brass LF, Molino M (2001) Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets. *Thromb Haemost* 85:533–538
154. Bank U, Reinhold D, Schneemilch C, Kunz D, Synowitz HJ, Ansorge S (1999) Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation. *J Interferon Cytokine Res* 19:1277–1287
155. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF (1991) Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. *J Biol Chem* 266:18846–18853

156. Tralau T, Meyer-Hoffert U, Schroder JM, Wiedow O (2004) Human leukocyte elastase and cathepsin G are specific inhibitors of C5a-dependent neutrophil enzyme release and chemotaxis. *Exp Dermatol* 13:316–325
157. Sadallah S, Hess C, Miot S, Spertini O, Lutz H, Schifferli JA (1999) Elastase and metalloproteinase activities regulate soluble complement receptor 1 release. *Eur J Immunol* 29:3754–3761
158. Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D (2004) Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. *J Immunol* 172:540–549
159. Hunter MG, Druhan LJ, Massullo PR, Avalos BR (2003) Proteolytic cleavage of granulocyte colony-stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony-stimulating factor receptor. *Am J Hematol* 74:149–155
160. Piper MG, Massullo PR, Loveland M, Druhan LJ, Kindwall-Keller TL, Ai J, Copelan A, Avalos BR (2010) Neutrophil elastase downmodulates native G-CSFR expression and granulocyte-macrophage colony formation. *J Inflamm (Lond)* 7:5
161. Halbwachs-Mecarelli L, Bessou G, Lesavre P, Renesto P, Chignard M (1996) Neutrophil serine proteases are most probably involved in the release of CD43 (leukosialin, sialophorin) from the neutrophil membrane during cell activation. *Blood* 87:1200–1202
162. Weber S, Babina M, Hermann B, Henz BM (1997) Leukosialin (CD43) is proteolytically cleaved from stimulated HMC-1 cells. *Immunobiology* 197:82–96
163. Le-Barillec K, Si-Tahar M, Balloy V, Chignard M (1999) Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. *J Clin Invest* 103:1039–1046
164. Doring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G (1995) Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. *J Immunol* 154:4842–4850
165. Duvoix A, Mackay RM, Henderson N, McGreal E, Postle A, Reid K, Clark H (2010) Physiological concentration of calcium inhibits elastase-induced cleavage of a functional recombinant fragment of surfactant protein D. *Immunobiology* 216:72–9
166. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S, Koller B, Reinhardt D, Roscher AA et al (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. *Nat Med* 13:1423–1430
167. van Kessel KP, van Strijp JA, Verhoef J (1991) Inactivation of recombinant human tumor necrosis factor- α by proteolytic enzymes released from stimulated human neutrophils. *J Immunol* 147:3862–3868
168. Bank U, Kupper B, Reinhold D, Hoffmann T, Ansorge S (1999) Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation. *FEBS Lett* 461:235–240
169. Leavell KJ, Peterson MW, Gross TJ (1997) Human neutrophil elastase abolishes interleukin-8 chemotactic activity. *J Leukoc Biol* 61:361–366
170. Champagne B, Tremblay P, Cantin A, St Pierre Y (1998) Proteolytic cleavage of ICAM-1 by human neutrophil elastase. *J Immunol* 161:6398–6405
171. Robledo O, Papaioannou A, Ochietti B, Beauchemin C, Legault D, Cantin A, King PD, Daniel C, Alakhov VY, Potworowski EF et al (2003) ICAM-1 isoforms: specific activity and sensitivity to cleavage by leukocyte elastase and cathepsin G. *Eur J Immunol* 33:1351–1360
172. Hermant B, Bibert S, Concord E, Dublet B, Weidenhaupt M, Vernet T, Gulino-Debrac D (2003) Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. *J Biol Chem* 278:14002–14012
173. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD et al (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. *Cell* 111:867–878

174. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB et al (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med* 16:887–896
175. Jackson PL, Xu X, Wilson L, Weathington NM, Clancy JP, Blalock JE, Gaggar A (2010) Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. *Mol Med* 16:159–166
176. Ai S, Cheng XW, Inoue A, Nakamura K, Okumura K, Iguchi A, Murohara T, Kuzuya M (2007) Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. *Biochem Biophys Res Commun* 364:395–401
177. Kurtagic E, Jedrychowski MP, Nugent MA (2009) Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. *Am J Physiol Lung Cell Mol Physiol* 296: L534–L546
178. Mydel P, Shipley JM, Adair-Kirk TL, Kelley DG, Broekelmann TJ, Mecham RP, Senior RM (2008) Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. *J Biol Chem* 283:9513–9522
179. Cooley J, McDonald B, Accurso FJ, Crouch EC, Remold-O'Donnell E (2008) Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease. *J Leukoc Biol* 83:946–955
180. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR et al (2010) Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. *Nat Med* 16:219–223
181. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL (2009) Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. *Blood* 114:1666–1674
182. Goulet B, Markovic Y, Leduy L, Nepveu A (2008) Proteolytic processing of cut homeobox 1 by neutrophil elastase in the MV4;11 myeloid leukemia cell line. *Mol Cancer Res* 6:644–653
183. Bagoly Z, Fazakas F, Komaromi I, Haramura G, Toth E, Muszbek L (2008) Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit. *Thromb Haemost* 99:668–674
184. Si-Tahar M, Pidard D, Balloy V, Moniatte M, Kieffer N, Van Dorsselaer A, Chignard M (1997) Human neutrophil elastase proteolytically activates the platelet integrin α IIb β 3 through cleavage of the carboxyl terminus of the α IIb subunit heavy chain. Involvement in the potentiation of platelet aggregation. *J Biol Chem* 272:11636–11647

Proteases and Their Receptors in Inflammation

Vergnolle, N.; Chignard, M. (Eds.)

2011, XIV, 310 p., Hardcover

ISBN: 978-3-0348-0156-0